Fertile battleThe new International Federation of Gynecology and Obstetrics (FIGO) ovulatory disorder classification: PRO and CON
Section snippets
PRO: For the new international federation of gynecology and obstetrics ovulatory disorder classification: If it ain't broke, don't fix it?
The new classification of disorders of ovulation has stirred up a healthy debate about the need for change and brings to mind the phrase from which the title of this article derives “I know it’s an ugly-looking antenna, but it gets the job done, and if it ain't broke, don't fix it” (1). The human condition, however, is about striving to improve what we have and enhance the utility of any available tools. To quote Henry Ford “We do
CON: Against the modified classification of women presenting with ovulatory disorders proposed by figo—Will it really change the future care of those patients?
The FIGO relies on opinions and consensus in the midst of a digital transformation, potentially allowing for a more accurate annotation and clearer classification of health conditions in an automated and replicable capacity? We believe that at the present time, a data-first, patient-centric approach to diagnostics, which uses electronic health records, imaging, biobanks, and
References (42)
The pathophysiology of polycystic ovary syndrome: trying to understand PCOS and its endocrinology
Best Pract Res Clin Obstet Gynaecol
(2004)- et al.
Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome
Fertil Steril
(2018) - et al.
CECERM study group. A revised prediction model for natural conception
Reprod Biomed Online
(2017) - et al.
Predicting pregnancy chances leading to term live birth in oligo/anovulatory women diagnosed with PCOS
Reprod Biomed Online
(2023) Attributed to Thomas Bertram Lance
(1977)- et al.
The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS)
Hum Reprod
(2004) WHO Scientific Group on Agents Stimulating Gonadal Function in the Human & World Health Organization. Agents stimulating gonadal function in the human: report of a WHO Scientific Group; 1972 August 28–September 1; Geneva. Geneva: World Health Organization 1973
Agents stimulating gonadal function in the human. Report of a WHO scientific group
World Health Organ Tech Rep Ser
(1976)National Institute for Health and Care Excellence (NICE). Fertility problems: assessment and treatment. Clinical guideline CG156. London: NICE and RCOG; 2013
A review of the pathophysiology of functional hypothalamic amenorrhoea in women subject to psychological stress, disordered eating, excessive exercise or a combination of these factors
Clin Endocrinol (Oxf)
The FIGO ovulatory disorders classification system
Fertil Steril
Ethnic specific PCOS
Expert Rev Endocrinol Metab
WHO recommendations for the management of anovulatory infertility in women with polycystic ovary syndrome (PCOS)
Hum Reprod Update
Large-scale genome-wide meta-analysis of polycystic ovary syndrome suggests shared genetic architecture for different diagnosis criteria
PLoS Genet
The genetics of polycystic ovary syndrome: an overview of candidate gene systematic reviews and genome-wide association studies
J Clin Med
DNA methylation in the pathogenesis of polycystic ovary syndrome
Reprod (Camb Engl)
Obesity-related DNA methylation at imprinted genes in human sperm: results from the TIEGER study
Clin Epigenetics
Male obesity effects on sperm and next-generation cord blood DNA methylation
PLoS One
Functional classification of patients selected for gonadotropic therapy
Obstet Gynecol
Classification of amenorrhoeic states and their treatment by ovulation induction
Clin Endocrinol (Oxf)
Cited by (3)
Real clinical practice of infertility treatment in Russia: а collective opinion of 425 reproductologists
2023, Obstetrics, Gynecology and Reproduction
A.H.B. reports that he was a coauthor of the FIGO Committee on Menstrual Disorders and Related Health Impacts system for classification of causes of ovulatory disorders. M.G.M. was a coauthor of the FIGO Committee on Menstrual Disorders and Related Health Impacts' system for classification of causes of ovulatory disorders; Consultant to AbbVie Inc, American Regent, Daiichi Sankyo, Myovant Sciences, and Pharmacosmos. H.C.O. has nothing to disclose. B.L. has nothing to disclose. B.C.J.M.F. has nothing to disclose.
Correspondence: Richard S. Legro, M.D., H103, Department of Obstetrics and Gynecology, Penn State College of Medicine, 500 University Drive, Hershey, PA 17033 (E-mail: [email protected]).
Disclaimer: Authors for “fertile battles” are chosen to represent the full breadth of opinions. Individual authors, even within one side of the debate, do not necessarily agree with all viewpoints expressed.